Items where authors include "Hajek, R"

Article

Ludwig, H L, Terpos, E, van de Donk, N et al. (26 more authors) (2023) Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. The Lancet Oncology, 24 (6). e255-e269. ISSN 1470-2045

Ludwig, H, Sonneveld, P, Facon, T et al. (33 more authors) (2021) COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. The Lancet Haematology, 8 (12). e934-e946. ISSN 2352-3026

Davies, F, Rifkin, R, Costello, C et al. (24 more authors) (2021) Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Annals of Hematology, 100 (9). pp. 2325-2337. ISSN 0939-5555

Moreau, P, Kumar, SK, San Miguel, J et al. (67 more authors) (2021) Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. The Lancet Oncology, 22 (3). e105-e118. ISSN 1470-2045

Terpos, E, Mikhael, J, Hajek, R et al. (13 more authors) (2021) Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer Journal, 11 (2). 40. ISSN 2044-5385

Terpos, E, Engelhardt, M, Cook, G orcid.org/0000-0001-7196-7364 et al. (15 more authors) (2020) Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia, 34. pp. 2000-2011. ISSN 0887-6924

Moreau, P, Sonneveld, P, Boccadoro, M et al. (13 more authors) (2019) Chimeric Antigen Receptor T-Cell Therapy For Multiple Myeloma: A Consensus Statement From The European Myeloma Network. Haematologica, 104 (12). pp. 2358-2360. ISSN 0390-6078

Dimopoulos, MA, Gay, F, Schjesvold, F et al. (24 more authors) (2019) Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet, 393 (10168). pp. 253-264. ISSN 0140-6736

Ludwig, H, Delforge, M, Facon, T et al. (29 more authors) (2018) Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 32 (7). pp. 1542-1560. ISSN 0887-6924

Proceedings Paper

Hajek, R, Terpos, E, Lee, HC et al. (20 more authors) (2018) Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) - Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Registry of Monoclonal Gammopathies (RMG). In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology .